Understand the source comparison
Top Selling Peptides November 2026: Category Comparison
The following table compares the highest-volume peptides across metabolic, tissue repair, and cognitive categories based on November 2026 order data from Real Peptides. Each peptide is evaluated by primary research application, mechanism of action, typical stu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the highest-volume peptides across metabolic, tissue repair, and cognitive categories based on November 2026 order data from Real Peptides. Each peptide is evaluated by primary research application, mechanism of action, typical study duration, and the clinical trial phase where it's most commonly used.
- Tirzepatide
- Metabolic research, weight loss, cardiovascular outcomes
- Dual GLP-1/GIP receptor agonist. Slows gastric emptying, enhances insulin sensitivity
- 48–72 weeks
- Phase 3 extension trials
- Remains the metabolic research standard with the most robust long-term safety data. Ideal for trials requiring regulatory-grade comparator arms
- BPC-157
- Tissue repair, gastric healing, tendon/ligament recovery
- Upregulates VEGF, modulates FAK-paxillin pathway for fibroblast migration
- 8–16 weeks
- Phase 1 and Phase 2
- Highest unit volume in November 2026. Mechanism is well-characterized but human efficacy data still emerging, making it essential for any tissue repair protocol
- TB-500
- Angiogenesis, wound healing, post-injury recovery
- Binds actin to prevent polymerization, enhances cell migration and ECM remodeling
- 8–12 weeks
- Strong preclinical evidence and growing Phase 2 data. Often stacked with BPC-157 in combination protocols for additive effects
- Retatrutide
- Weight loss, NASH resolution, cardiometabolic research
- Triple GLP-1/GIP/glucagon receptor agonist
- 48–96 weeks
- Phase 2 and early Phase 3
- Highest recorded weight loss in any incretin trial (24.2% at 48 weeks). Essential for any comparative metabolic study in 2026–2027
- Dihexa
- Cognitive enhancement, TBI recovery, neurodegenerative disease models
- HGF receptor agonist promoting synaptogenesis and neuronal growth
- 12–24 weeks
- Phase 1 and preclinical
- Seven orders of magnitude more potent than BDNF in synaptic formation. Small doses produce measurable effects, making it cost-effective for long-term studies
- Survodutide
- NASH resolution, hepatic inflammation, metabolic dysfunction
- Dual GLP-1/glucagon receptor agonist with hepatic-specific anti-inflammatory effects
- 24–48 weeks
- Phase 2
- Differentiates from tirzepatide by showing liver fibrosis improvement independent of weight loss. Critical for NAFLD/NASH-focused trials